Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
Histogen Inc. (NASDAQ: HSTO) has announced that its financial results for the second quarter will be released after the market closes on August 11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO) has announced that its financial results for the second quarter will be released after the market closes on August 11, 2021. The company focuses on developing innovative restorative therapeutics aimed at promoting the body’s natural healing processes. Histogen’s technology utilizes cell-conditioned media and extracellular matrix materials, with applications in areas such as joint cartilage regeneration and hair growth.
Positive
- Potential for first-in-class restorative therapeutics.
- Innovative technology platform utilizing cell-conditioned media.
Negative
- None.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was +1.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including joint cartilage regeneration, spinal disk repair, hair growth and dermal rejuvenation. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.